Periodic Reporting for period 1 - Separative (Disruptive purification consumables for the pharmaceutical industry)
Reporting period: 2018-03-01 to 2018-07-31
The technology was validated by an independent laboratory. The manufacturing process internally developed and assessed, including an industrial pilot plant, demonstrated some strong productivity and cost-effectiveness potential. On this basis, the industrialization was the next step to ensure the reproducibility of the manufacturing, reach the market performances expectations, and make the process scalable.
The SME Phase 1 involved an industrialization study including an automation study, a value chain organization analysis and a marketing mix review.
- a more accurate knowledge of the market expectations,
- the automation of the key steps of the manufacturing process,
- the definition of the control process,
- the design of the next version of the pilot plan,
- the selection of the key suppliers.
The expected results are the industrialization validation and the gathering of the expected conditions to initiate an optimization program of the product to improve its performances.
Bringing the product to the market will provide several technological advantages to the healthcare industry: better quality of drugs due to higher purity, lower investments for production plants (savings of 59% for separation), lower manufacturing costs due to better yields (no losses of valuable material in process) and higher security of manufacturing process due to lower volumes of flammable and toxic solvents.